|
 |
ActiqThis page contains recent news articles, when available, and an overview of Actiq but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Actiq (when available) Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy. Mechanism Of Action: Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. News Articles on Fentanyl Cephalon Convinces the Continent - Apr 16, 2008 ...revenue last year, even in the face of generic competition from Barr Pharmaceuticals (NYSE: BRL) on Cephalon's first-generation Actiq fentanyl compound. Motley Fool Disposing of medications, responsibly - Apr 17, 2008 They include powerful painkillers such as Actiq, Duragesic Transdermal patches, OxyContin tablets, Percocet, Fentora, and more. For a complete list, Chicago Tribune, NY wants drug companies to help dispose of old medication - Apr 18, 2008 According to the US Food and Drug Administration, the following should be flushed down the toilet: Actiq, Daytrana Transdermal Patch, Duragesic transdermal Press & Sun-Bulletin, Cephalon Announces European Commission Approval of EFFENTORA for ... - Apr 14, 2008 GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. PR Newswire UK (press release), Cephalon CEO gets $16M compensation - Mar 24, 2008 ...million to settle one of two investigations related to improper marketing of Provigil, as well as epilepsy drug Gabitril and cancer pain reliever Actiq. BusinessWeek New drug subsidies to benefit Coast patients - Apr 1, 2008 About 8000 cancer patients in Australia can replace morphine doses and its side effects with newly available fentanyl lozenges (Actiq), which will cost the Sunshine Coast Daily, BioDelivery Sciences To Present BEMA(TM) Fentanyl Data At The 24th ... - Feb 13, 2008 Actiq®, also known as oral transmucosal fentanyl citrate, is a solid formulation of fentanyl citrate on a handle that is designed to be slowly dissolved in Medical News Today (press release), Cephalon profit beats Street, shares rise - Feb 12, 2008 But sales of cancer pain drug Actiq fell 50 percent to $54.3 million as it faced competition from cheaper generic versions of the medicine. Guardian Unlimited, Cephalon Swings to 4th-Quarter Profit - Feb 12, 2008 ...it was marketing the epilepsy drug Gabitril, narcolepsy drug Provigil and cancer pain reliever Actiq for uses for which they were not yet approved. Houston Chronicle, Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance - Feb 12, 2008 ...of $512.6 million, a decrease of only 22 percent despite a full year of generic competition to ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. PR Newswire (press release), Drug firm sued over generic action - Feb 14, 2008 Cephalon produces several products in Salt Lake City, including Actiq. Provigil, which accounts for about half of Cephalon's total sales, treats excessive Deseret News, More News - Feb 10, 2008 Prescribed examples are Duragesic, which is a patch, and Actiq, which is a lollipop. n Oxycodone — A synthetic opiate and the narcotic found in OxyContin Scranton Times-Tribune, inVentiv Selling Solutions Selected to Provide Sales Team for ... - Mar 6, 2008 GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. SunHerald.com, FTC Alleges Cephalon's Deals Blocked Generics from Market - Feb 14, 2008 ...amid accusations that the firm aggressively promoted its drugs, including Provigil and pain drug Actiq, for non-FDA-approved indications. BioWorld Online, Cephalon shares rise after earnings - Feb 13, 2008 Cancer pain drug Actiq sales fell to $240 million for the year from $572.1 million in 2006, due to generic competition. Fentora sales were $33.9 million in Philadelphia Inquirer, Cephalon Posts Q4 Profit On Lower Expenses; Guides Q1, Reiterates ... - Feb 12, 2008 Sales of cancer pain drug Actiq dropped 50% to $54.3 million due to generic competition. Pain drug Fentora sold 16% more at $33.9 million. RTT News, Cephalon Provides Update on Regulatory Status of the FENTORA ... - Jan 25, 2008 GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. CNNMoney.com Prescription drug abuse increasing among teens - Jan 9, 2008 Known commercially as Actiq, Duragesic, and Sublimaze, this prescription drug is used to treat patients with severe pain, manage pain after surgery, The County Press, Lidoderm(R) Unseats OxyContin(R) to Top The Hartford's New List of ... - Dec 10, 2007 The average per-dose price of Actiq (#7), already the most expensive drug used for workers’ compensation patients, rose 70 percent, and the anti-depressant WELT ONLINE, FDA Considers Allowing Off-Label Promotion - Dec 3, 2007 This summer Cephalon was accused of off-label marketing of their pain medications Fentora and Actiq. Four deaths were attributed to off-label use of Fentora InjuryBoard.com, TREANDA Significantly Improves Clinical Outcomes in Patients with ... - Dec 10, 2007 GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. CNNMoney.com WASTED YOUTH - UPDATE: A drug more potent than heroin - Dec 15, 2007 Fentanyl is typically used to treat people with severe pain, and is prescribed under the names Actiq, Duragesic or Sublimaze, according to the National The Patriot Ledger, Flushing meds: A good idea? - Dec 6, 2007 According to the current federal guidelines, only certain drugs should be flushed, including Actiq (fentanyl citrate), OxyContin tablets (oxycodone) and Chicago Tribune, Fentora Off-Label Marketing Charges Settled, Now Cephalon Wants to ... - Nov 13, 2007 That same year, the Connecticut Attorney General discovered that Cephalon marketed Actiq for off-label use—purposes other than the drug’s intention—and set Newsinferno.com, Cephalon Announces Strong Third Quarter Financial Results - Nov 8, 2007 Entrance into the market of an additional generic version of ACTIQ by mid-2008; -- Approval of TREANDA and mid-2008 launch; -- Reduction of interest income CNNMoney.com Cephalon pays $425 million to settle claims of off-label marketing - Nov 13, 2007 Actiq is approved by the FDA for use in cancer patients but is often prescribed by physicians off-label for other types of pain, such as migraine headaches. Medical Marketing and Media, Cephalon Pays $425 Million For Off-Label Marketing Dispute - Nov 13, 2007 Allegations of off-label marketing have been suggested in the case of both Fentora and Actiq. Allegedly Fentora and Actiq were marketed as acceptable drugs InjuryBoard.com, Cephalon Gains Ground on Higher Outlooks - Nov 9, 2007 ...and Fentora) offset by better-than-expected sales in products expected to be cannibalized by generic competition (Actiq and generic Actiq)," he said. Houston Chronicle, UPDATE 1-Cephalon posts loss, agrees to settle probes - Nov 8, 2007 The probes into Cephalon's sales and marketing practices involved extensive off-label use of some of its products, including Actiq and its flagship sleep Reuters Cephalon to settle US, state probes: It will pay $425 million ... - Nov 9, 2007 Sales of the company's pain medications, including Actiq, which is facing generic competition, sank 33 percent. Actiq sales were $56 million, compared with Trading Markets (press release), Cephalon Settles Probe, Ups Forecast - Nov 9, 2007 ...for "off-label" sales and marketing practices of its drugs _ epilepsy drug Gabitril, narcolepsy drug Provigil and cancer pain reliever Actiq. Houston Chronicle, Cephalon Wheels and Deals - Nov 9, 2007 Adjusted net income declined 30% because of increasing competition from Barr Pharmaceuticals (NYSE: BRL) and its generic version of Cephalon's ACTIQ Motley Fool Cephalon Records Big Charge To Settle Probe of Its Marketing - Nov 9, 2007 ...take the charge as part of a settlement to one of the investigations into off-label marketing of its pain relievers Fentora and its predecessor, Actiq. Wall Street Journal Cephalon Swings to 3Q Loss on Settlement - Nov 8, 2007 Sales of the company's pain drug, which includes Actiq, plunged 33 percent to $121.8 million on generic competition. Sales of central nervous system drugs CNNMoney.com Cephalon settles drug marketing probe for $425M - Nov 8, 2007 Investigators were also looking at whether Cephalon marketed its pain medicine Actiq, which is only approved for use in cancer patients, for other types of Bizjournals.com, Barr's 3Q profit falls on charges - Nov 8, 2007 The increase in sales is partly attributed to Pliva's product line and a generic version of Actiq launched in 2006. Meanwhile, sales of the company's CNNMoney.com Cephalon pays $425 million to settle sales practices probe - Nov 9, 2007 Provigil advanced 10% to $217.1 million, but Actiq collapsed 69% to $55.9 million as a result of generic competition. Neverthless, its follow-up drug to Pharma Times (subscription), Cephalon to pay $425M to settle investigations - Nov 8, 2007 In September 2004, the US attorney in Philadelphia subpoenaed documents about Cephalon's sales and marketing of pain medication Actiq and two other products Philadelphia Inquirer, Cephalon Submits Supplemental New Drug Application for FENTORA - Nov 12, 2007 ...oral fentanyl products, including oral transmucosal fentanyl citrate (OTFC and Actiq(R)), to FENTORA, do not substitute FENTORA on a mcg per mcg basis. CNNMoney.com Cephalon Announces Strong Third Quarter Financial Results - Nov 9, 2007 ...to $230.9 million and the pain franchise reported strong sales of $121.8 million, a decrease of only 33 percent despite generic competition to ACTIQ(R). PharmaLive.com (press release), Cephalon Settles Drug Marketing Investigation for $425 Million - Nov 14, 2007 ...asked Cephalon for promotional and research information for its narcotic painkillers Actiq (oral transmucosal fentanyl citrate) and Fentora (fentanyl FDA news (subscription), Health Highlights: Nov. 10, 2007 - Nov 11, 2007 ...practices for three of its drugs, Gabitril -- used to treat epilepsy-- narcolepsy drug Provigil and Actiq, which is marketed to relieve cancer pain. Atlanta Journal Constitution, Barr Reports Third Quarter 2007 GAAP Earnings of $0.36 Per Share ... - Nov 8, 2007 The increase also reflects strong sales of Fentanyl Citrate, a generic version of ACTIQ(R) that we launched in late September 2006. CNNMoney.com Cephalon Appoints Valli F. Baldassano as Executive Vice President ... - Nov 1, 2007 GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. CNNMoney.com TO THE POINT - Nov 8, 2007 The company's generic product sales doubled to $434 mil on its Pliva product, a knockoff of Actiq. It sees Q4 EPS of 73-83 cents vs. views of 83 cents. Investor's Business Daily (subscription) Magic Software Turns To Profit In Q3, Revenues Up, Expenses ... - Nov 8, 2007 The increase also reflects strong sales of Fentanyl Citrate, a generic version of ACTIQ that we launched in late September 2006. For the nine months period, RTT News, Provigil Warnings Added For Serious Skin Rashes, Psychiatric Problems - Oct 25, 2007 ...allegedly promoting off-label uses for Provigil. The company has also been investigated for promoting its painkillers Fentora and Actiq in the same manner. Newsinferno.com, ã€?页é?¢è°ƒè‰²ç‰ˆ - Oct 23, 2007 ...(tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ? (oral transmucosal fentanyl citrate) [C-II]. The company also markets 金èž?ç•Œ, Brand Names/Synonyms: Actiq is also known by the following brand names and/or synonymsActiq; CHEMBANK1683; Dea No. 9801; Duragesic; Duragesic-100; Durogesic; F5886; Fentanest; Fentanil; Fentanil [Dcit]; Fentanila; Fentanila [Inn-Spanish]; Fentanyl; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Fentanylum; Fentanylum [Inn-Latin]; HSDB 3329; Pentanyl; Phentanyl; R 4263; Sentonil; Sublimaze; Sublimaze Preservative Free Drug Category: Actiq is categorized under the following by the FDA: Anesthetics; Narcotics; Adjuvants; Analgesics; Opiate Agonists; ATC:N01AH01; ATC:N02AB03 Dosage Forms: DISC (SUSTAINED-RELEASE); LIQUID; SOLUTION Absorption: Not Available Interactions: Interactions for Fentanyl: Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC® is given concurrently with agents that affect CYP3A4 activity. Coadminstration with agents that induce 3A4 activity may reduce the efficacy of DURAGESIC®. The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations. The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression. In this situation, special patient care and observation are appropriate. Central Nervous System Depressants The concomitant use of DURAGESIC® (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death. When such combined therapy is contemplated, the dose of one or both agents should be significantly reduced. MAO Inhibitors DURAGESIC® is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics. -->Chemical IUPAC Name: N-(1-phenethyl-4-piperidyl)-N-phenyl-propanamide : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |